The goal of this clinical trial is to learn if the antibody drug HuL001, combined with
Lenalidomide/Dexamethasone works to treat Multiple Myeloma patients. It will also learn about the safety and tolerability of the therapeutic combination. The objectives of this study are:
1. To evaluate the safety and tolerability of HuL001 (in combination with Len/Dex).
2. To evaluate the efficacy of HuL001 (in combination with Len/Dex).
Researchers will use the antibody drug HuL001, combined with Len/Dex, to see if this works for Multiple Myeloma therapy.
Participants will:
* Receive HuL001 antibody injections every 2 weeks
* Take Lenalidomide for 21 consecutive days each month
* Take Dexamethasone every 1 week
* Visit the clinic on scheduled days for checkups and tests
* Keep a diary of their symptoms and Myeloma responses.